MedTrace Logo

PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty

NCT03372278 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-06-15

No results posted yet for this study

Summary

This study is a multicenter, prospective, non-controlled post market clinical follow-up study. The objectives of this study are to confirm the safety and performance of the commercially available Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty.

Conditions

  • Rheumatoid Arthritis With Adequate Bone Quality
  • Inflammatory Arthritis
  • Osteoarthritis, Hip
  • Avascular Necrosis
  • Post-traumatic; Arthrosis
  • Congenital Hip Dysplasia

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hassan Achakri · Zimmer Biomet

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2027-01-31
Completion
2028-12-31

Countries

  • Australia
  • Belgium
  • Canada
  • Finland
  • France
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03372278 on ClinicalTrials.gov